Casandra
Casandra Test Code LC92657Version 1 (DRAFT)
Performing Lab
Lab LabcorpLab Test ID 451949
PD-L1, IHC (Atezolizumab), Non-Small-cell Lung Cancer
Also known as: Programmed Death Ligand 1, Tecentriq™
Clinical Use
Order TestUse
The PD-L1 (SP142) is a qualitative IHC assay intended for use in the detection of PD-L1 in formalin-fixed, paraffin embedded (FFPE) in non-small-cell lung cancer tissue samples using the Ventana BenchMark Ultra Platform.
Special Instructions
Not provided.
Limitations
Not provided.
Test Details
Methodology
Immunohistochemistry using Ventana BenchMark Ultra.
Biomarkers
Targets not provided.
LOINC Codes
Order Codes
- 85149-3 - PD-L1 by SP142 Tiss ImStn Doc
Result Codes
- 83797-1 - MD Referral note
- 82607-3 - Clinical data TmStpRange
- 39111-0 - Bdy site
- 66746-9 - Specimen type
- 77202-0 - Laboratory comment Report
- 83053-9 - Cells.PD-L1/Viab tum NFr Tiss ImStn
- 59465-5 - Path Rev
- 83057-0 - PD-L1 by SP142 Tiss Ql ImStn
- 8262-8 - Service Cmnt 02-Imp
- 62364-5 - Test performance info Spec
- 11502-2 - Laboratory report
Result Turnaround Time
6-10 days
Related Documents
For more information, please review the documents below
Specimen Requirements
Specimen
Unknown
Volume
Not provided
Minimum Volume
Not provided
Causes for Rejection
Slides sectioned more than two months prior to test request and not stored at 15°C to 30°C
Similar Tests
Other tests from different labs that may be relevant
PD‑L1 Lung (Atezolizumab), IHC
Quest Diagnostics
PD-L1 Non-Lung (Nivolumab) IHC
Quest Diagnostics
PD-L1 SP263 FDA for NSCLC
NeoGenomics
PD‑L1 Lung (Nivolumab), IHC
Quest Diagnostics
PD‑L1 Lung (Pembrolizumab or Cemiplimab), IHC
Quest Diagnostics
PD-L1 SP142 FDA (TECENTRIQ®) for NSCLC
NeoGenomics
PD-L1 (SP263), technical only
MPLN
PD-L1 IHC with Interpretation
Quest Diagnostics
PD-L1 (SP142)
MPLN
PD‑L1 28‑8 FDA for NSCLC
NeoGenomics